Syncor's mid-year results improve
Radiopharmacy firm Syncor International reported improving marginson the strength of continued sales growth through the first halfof 1995. Net sales for the six months ended June 30 increased6.1%, to $166.3 million. Net income for the period was $2.3
Radiopharmacy firm Syncor International reported improving marginson the strength of continued sales growth through the first halfof 1995. Net sales for the six months ended June 30 increased6.1%, to $166.3 million. Net income for the period was $2.3 million,compared to $2.8 million in the first half of 1994.
In the second quarter of 1995, net sales increased 1.7% to $83.3million. Net income for the second quarter was $1.3 million, comparedto $700,000 for the same period last year.
Results through June put the company on track to meet Syncor's1995 financial objectives, according to chief executive Gene McGrevin.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
